{"ticker": {"uuid": "b4038125-500a-4e79-871e-b5c6efcc93e3", "symbol": "QTTB", "name": "Q32 Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form 424B5 Q32 Bio Inc For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOWFlYcGZMdkFOYWNXbjZocG5FLVdaYlZPdzlMaUI3VUFWa0tEVllKOC14RHpuMHRoaHZGVnVuVU9keF9ZWWtWXzlEYlR1RjFwa0FiekxXNzZVbm9lQkE1RnBsMTYzWl9hT0ZhZ2tYUHR0RmZLRlV0cHZxcXRfTWdaS3FuWWtzYzExanlkckR5ck45dElxb1RjTDdjZw?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T21:40:18+00:00", "published_display": "15 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal", "summary": "Q32 Bio (Nasdaq: QTTB) announced a public offering totaling $187.6 million, or up to $215.8 million if underwriters exercise their full option. The offering includes 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants for 4,931,506 shares at $18.2499 per ", "url": "https://www.stocktitan.net/sec-filings/QTTB/8-k-q32-bio-inc-reports-material-event-1551c902bad1.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:19:31", "published_display": "15 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio (QTTB) Launches $200M Public Offering to Fund Clinical Development", "summary": "Q32 Bio Inc (QTTB) announced a $200 million public offering, selling common stock and pre-funded warrants to fund clinical trials for bempikibart, a drug targeting autoimmune and inflammatory diseases. Despite a low GF Score of 17/100, the company exhibits strong financial health", "url": "https://www.gurufocus.com/news/8959458/q32-bio-qttb-launches-200m-public-offering-to-fund-clinical-development", "source_name": "GuruFocus", "published_at": "2026-07-15T06:41:31", "published_display": "15 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "Q32 Bio Inc. announced the pricing of a public offering expected to raise approximately $200 million. The offering includes shares of common stock at $18.25 per share and pre-funded warrants at $18.2499 per warrant, with an option for underwriters to purchase additional shares. T", "url": "https://www.prnewswire.com/news-releases/q32-bio-announces-pricing-of-200-million-public-offering-of-common-stock-and-pre-funded-warrants-302825849.html", "source_name": "PR Newswire", "published_at": "2026-07-15T02:40:53", "published_display": "15 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company, has announced a proposed underwritten public offering of $200 million in common stock and pre-funded warrants. The company also intends to grant underwriters a 30-day option to purchase an additional $30 million", "url": "https://www.prnewswire.com/news-releases/q32-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302824166.html", "source_name": "PR Newswire", "published_at": "2026-07-13T20:11:13", "published_display": "13 Jul 2026 20:11", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet", "summary": "Q32 Bio Inc. (QTTB) stock recently surged by 67.91% due to increased investor optimism and significant volatility. The company holds about $51 million in cash with low debt, providing a solid financial runway despite ongoing operating losses. This makes QTTB a playground for mome", "url": "https://stockstotrade.com/news/q32-bio-inc-qttb-news-2026_07_13/", "source_name": "StocksToTrade", "published_at": "2026-07-13T10:02:00", "published_display": "13 Jul 2026 10:02", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio stock surges 60% on positive alopecia areata trial data", "summary": "Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% after reporting positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe alopecia areata. The trial met its primary endpoint, showing a significant reduction in SALT ", "url": "https://www.investing.com/news/stock-market-news/q32-bio-stock-surges-60-on-positive-alopecia-areata-trial-data-93CH-4788036", "source_name": "Investing.com", "published_at": "2026-07-13T07:04:00", "published_display": "13 Jul 2026 07:04", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Q32 Bio (QTTB.US)$ thank market left 30 %", "summary": "A user on the moomoo Community platform posted a brief comment regarding Q32 Bio (QTTB.US), stating \"thank market left 30 %.\" This post was made by user \"Revi2020\" and was part of a discussion about sharing profit/loss on the platform, indicating a significant drop in the stock's", "url": "https://www.moomoo.com/community/feed/q32-bio-qttb-us-thank-market-left-30-116910656585734", "source_name": "Moomoo", "published_at": "2026-07-13T04:10:08", "published_display": "13 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. QTTB Extends Volatile Rally As Traders Eye Key Levels", "summary": "Q32 Bio Inc. (QTTB) is experiencing a volatile uptrend, with its stock price increasing by 15.57% on July 12, 2026, driven by positive news and strong investor interest. Despite robust gross margins and liquidity, the company faces ongoing losses and dilution risks due to negativ", "url": "https://stockstotrade.com/news/q32bioinc-qttb-news-2026_07_12/", "source_name": "StocksToTrade", "published_at": "2026-07-12T15:40:46", "published_display": "12 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. QTTB Stock Jumps After Volatile Spike Draws Trader Focus", "summary": "Q32 Bio Inc. (QTTB) stock is experiencing a volatile jump, trading up 15.57% due to investor optimism over pivotal autoimmune drug trial results. Despite strong gross margins and liquidity, the company faces significant losses and operating cash burn, making it a speculative stoc", "url": "https://www.timothysykes.com/news/q32bioinc-qttb-news-2026_07_12/", "source_name": "www.timothysykes.com", "published_at": "2026-07-12T11:08:00", "published_display": "12 Jul 2026 11:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026", "summary": "Q32 Bio (Nasdaq: QTTB) is scheduled to announce 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe or very severe alopecia areata on Monday, July 13, 2026. Following the announcement, the clinical stage biotechnolo", "url": "https://finance.yahoo.com/healthcare/articles/q32-bio-report-36-week-200500427.html", "source_name": "Market source", "published_at": "2026-07-10T20:10:39", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. (QTTB) gains Boxer Capital group as 13.3% shareholder", "summary": "A group led by Boxer Capital Management, LLC has reported a 13.3% beneficial ownership stake in Q32 Bio Inc. (QTTB), amounting to 3,149,310 shares of common stock as of June 30, 2026. This ownership, held with shared voting and dispositive power, is considered a passive investmen", "url": "https://www.stocktitan.net/sec-filings/QTTB/schedule-13g-q32-bio-inc-passive-investment-disclosure-5-8f0acbdaa5bd.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:10:39", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM:QTTB) added to Russell Microcap Value Benchmark Index", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been included in the Russell Microcap Value Benchmark Index as of June 29, 2026. This addition indicates the company's growing recognition in the financial markets, following recent activities such as a mixed shelf filing and private placement fi", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af026", "source_name": "marketscreener.com", "published_at": "2026-06-29T16:11:15", "published_display": "29 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Growth Benchmark Index", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been added to the Russell Microcap Growth Benchmark Index. The biotechnology company focuses on developing therapies for autoimmune and inflammatory diseases, with its lead candidate bempikibart (ADX-914) currently in a Phase 2 program for alopec", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df427", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:11:53", "published_display": "29 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Index", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been included in the Russell Microcap Index, a significant development for the clinical-stage biotechnology company. This inclusion follows its addition to the Russell Microcap Growth Benchmark Index and Russell 3000E Growth Benchmark Index. The ", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-microcap-index-ce7f5fdedd88fe21", "source_name": "marketscreener.com", "published_at": "2026-06-29T06:11:53", "published_display": "29 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell 3000E Value Benchmark", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been added to several Russell indices, including the Russell 3000E Value Benchmark, Russell Microcap Value Benchmark, and Russell Microcap Growth Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing therapies for aut", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-3000e-value-benchmark-ce7f5fddd98bf22c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:10:00", "published_display": "29 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Q32 Bio Inc For: 25 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPdW14akRwREpraEJVS3ZkdHZ5SDBWbkQ2SFN4ZmIya0lpRTJiSmFFN0hsRUhoc1dLM21SMkZYT0ZIWVFGX0VuT1pMNGhoWjhFbmNQaFZYX21KbXRkdktRUkNGNWVsT2ZxZG94VEdDNlBsSlBFT2VZb3kzZnR0THVGQktwMzJEUW5OekRkc09leTdtMlRFVDQw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T01:14:15+00:00", "published_display": "26 Jun 2026 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. Common Stock (QTTB) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFAzVndnVHNlYm5pU1U1alhaTE12b1VfX29neWpLd1JxcTh6OTJ6OVBFSk9BaHczYlVKYWx4eUJkUDA1UUVnZWdqb2JWOElmTnRWNkhOMm1rNA?oc=5", "source_name": "Gotrade", "published_at": "2026-05-30T05:30:43+00:00", "published_display": "30 May 2026 05:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio (QTTB) Is Up 126.6% After US$55M Private Placement With Top Healthcare Funds - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Form 424B5 Q32 Bio Inc For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOWFlYcGZMdkFOYWNXbjZocG5FLVdaYlZPdzlMaUI3VUFWa0tEVllKOC14RHpuMHRoaHZGVnVuVU9keF9ZWWtWXzlEYlR1RjFwa0FiekxXNzZVbm9lQkE1RnBsMTYzWl9hT0ZhZ2tYUHR0RmZLRlV0cHZxcXRfTWdaS3FuWWtzYzExanlkckR5ck45dElxb1RjTDdjZw?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T21:40:18+00:00", "published_display": "15 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal", "summary": "Q32 Bio (Nasdaq: QTTB) announced a public offering totaling $187.6 million, or up to $215.8 million if underwriters exercise their full option. The offering includes 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants for 4,931,506 shares at $18.2499 per ", "url": "https://www.stocktitan.net/sec-filings/QTTB/8-k-q32-bio-inc-reports-material-event-1551c902bad1.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:19:31", "published_display": "15 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio (QTTB) Launches $200M Public Offering to Fund Clinical Development", "summary": "Q32 Bio Inc (QTTB) announced a $200 million public offering, selling common stock and pre-funded warrants to fund clinical trials for bempikibart, a drug targeting autoimmune and inflammatory diseases. Despite a low GF Score of 17/100, the company exhibits strong financial health", "url": "https://www.gurufocus.com/news/8959458/q32-bio-qttb-launches-200m-public-offering-to-fund-clinical-development", "source_name": "GuruFocus", "published_at": "2026-07-15T06:41:31", "published_display": "15 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "Q32 Bio Inc. announced the pricing of a public offering expected to raise approximately $200 million. The offering includes shares of common stock at $18.25 per share and pre-funded warrants at $18.2499 per warrant, with an option for underwriters to purchase additional shares. T", "url": "https://www.prnewswire.com/news-releases/q32-bio-announces-pricing-of-200-million-public-offering-of-common-stock-and-pre-funded-warrants-302825849.html", "source_name": "PR Newswire", "published_at": "2026-07-15T02:40:53", "published_display": "15 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company, has announced a proposed underwritten public offering of $200 million in common stock and pre-funded warrants. The company also intends to grant underwriters a 30-day option to purchase an additional $30 million", "url": "https://www.prnewswire.com/news-releases/q32-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302824166.html", "source_name": "PR Newswire", "published_at": "2026-07-13T20:11:13", "published_display": "13 Jul 2026 20:11", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet", "summary": "Q32 Bio Inc. (QTTB) stock recently surged by 67.91% due to increased investor optimism and significant volatility. The company holds about $51 million in cash with low debt, providing a solid financial runway despite ongoing operating losses. This makes QTTB a playground for mome", "url": "https://stockstotrade.com/news/q32-bio-inc-qttb-news-2026_07_13/", "source_name": "StocksToTrade", "published_at": "2026-07-13T10:02:00", "published_display": "13 Jul 2026 10:02", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio stock surges 60% on positive alopecia areata trial data", "summary": "Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% after reporting positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe alopecia areata. The trial met its primary endpoint, showing a significant reduction in SALT ", "url": "https://www.investing.com/news/stock-market-news/q32-bio-stock-surges-60-on-positive-alopecia-areata-trial-data-93CH-4788036", "source_name": "Investing.com", "published_at": "2026-07-13T07:04:00", "published_display": "13 Jul 2026 07:04", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Q32 Bio (QTTB.US)$ thank market left 30 %", "summary": "A user on the moomoo Community platform posted a brief comment regarding Q32 Bio (QTTB.US), stating \"thank market left 30 %.\" This post was made by user \"Revi2020\" and was part of a discussion about sharing profit/loss on the platform, indicating a significant drop in the stock's", "url": "https://www.moomoo.com/community/feed/q32-bio-qttb-us-thank-market-left-30-116910656585734", "source_name": "Moomoo", "published_at": "2026-07-13T04:10:08", "published_display": "13 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. QTTB Extends Volatile Rally As Traders Eye Key Levels", "summary": "Q32 Bio Inc. (QTTB) is experiencing a volatile uptrend, with its stock price increasing by 15.57% on July 12, 2026, driven by positive news and strong investor interest. Despite robust gross margins and liquidity, the company faces ongoing losses and dilution risks due to negativ", "url": "https://stockstotrade.com/news/q32bioinc-qttb-news-2026_07_12/", "source_name": "StocksToTrade", "published_at": "2026-07-12T15:40:46", "published_display": "12 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. QTTB Stock Jumps After Volatile Spike Draws Trader Focus", "summary": "Q32 Bio Inc. (QTTB) stock is experiencing a volatile jump, trading up 15.57% due to investor optimism over pivotal autoimmune drug trial results. Despite strong gross margins and liquidity, the company faces significant losses and operating cash burn, making it a speculative stoc", "url": "https://www.timothysykes.com/news/q32bioinc-qttb-news-2026_07_12/", "source_name": "www.timothysykes.com", "published_at": "2026-07-12T11:08:00", "published_display": "12 Jul 2026 11:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026", "summary": "Q32 Bio (Nasdaq: QTTB) is scheduled to announce 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe or very severe alopecia areata on Monday, July 13, 2026. Following the announcement, the clinical stage biotechnolo", "url": "https://finance.yahoo.com/healthcare/articles/q32-bio-report-36-week-200500427.html", "source_name": "Market source", "published_at": "2026-07-10T20:10:39", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. (QTTB) gains Boxer Capital group as 13.3% shareholder", "summary": "A group led by Boxer Capital Management, LLC has reported a 13.3% beneficial ownership stake in Q32 Bio Inc. (QTTB), amounting to 3,149,310 shares of common stock as of June 30, 2026. This ownership, held with shared voting and dispositive power, is considered a passive investmen", "url": "https://www.stocktitan.net/sec-filings/QTTB/schedule-13g-q32-bio-inc-passive-investment-disclosure-5-8f0acbdaa5bd.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:10:39", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM:QTTB) added to Russell Microcap Value Benchmark Index", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been included in the Russell Microcap Value Benchmark Index as of June 29, 2026. This addition indicates the company's growing recognition in the financial markets, following recent activities such as a mixed shelf filing and private placement fi", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af026", "source_name": "marketscreener.com", "published_at": "2026-06-29T16:11:15", "published_display": "29 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Growth Benchmark Index", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been added to the Russell Microcap Growth Benchmark Index. The biotechnology company focuses on developing therapies for autoimmune and inflammatory diseases, with its lead candidate bempikibart (ADX-914) currently in a Phase 2 program for alopec", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df427", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:11:53", "published_display": "29 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Index", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been included in the Russell Microcap Index, a significant development for the clinical-stage biotechnology company. This inclusion follows its addition to the Russell Microcap Growth Benchmark Index and Russell 3000E Growth Benchmark Index. The ", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-microcap-index-ce7f5fdedd88fe21", "source_name": "marketscreener.com", "published_at": "2026-06-29T06:11:53", "published_display": "29 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell 3000E Value Benchmark", "summary": "Q32 Bio Inc. (NasdaqCM: QTTB) has been added to several Russell indices, including the Russell 3000E Value Benchmark, Russell Microcap Value Benchmark, and Russell Microcap Growth Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing therapies for aut", "url": "https://www.marketscreener.com/news/q32-bio-inc-nasdaqcm-qttb-added-to-russell-3000e-value-benchmark-ce7f5fddd98bf22c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:10:00", "published_display": "29 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Q32 Bio Inc For: 25 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPdW14akRwREpraEJVS3ZkdHZ5SDBWbkQ2SFN4ZmIya0lpRTJiSmFFN0hsRUhoc1dLM21SMkZYT0ZIWVFGX0VuT1pMNGhoWjhFbmNQaFZYX21KbXRkdktRUkNGNWVsT2ZxZG94VEdDNlBsSlBFT2VZb3kzZnR0THVGQktwMzJEUW5OekRkc09leTdtMlRFVDQw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T01:14:15+00:00", "published_display": "26 Jun 2026 01:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio Inc. Common Stock (QTTB) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFAzVndnVHNlYm5pU1U1alhaTE12b1VfX29neWpLd1JxcTh6OTJ6OVBFSk9BaHczYlVKYWx4eUJkUDA1UUVnZWdqb2JWOElmTnRWNkhOMm1rNA?oc=5", "source_name": "Gotrade", "published_at": "2026-05-30T05:30:43+00:00", "published_display": "30 May 2026 05:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q32 Bio (QTTB) Is Up 126.6% After US$55M Private Placement With Top Healthcare Funds - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 27, "sentiment_summary": {"positive": 10, "negative": 2, "neutral": 15, "score": 58, "total": 27, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 6.05, "count": 11}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 10, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 11.21, "latest_week": "2026-07-10", "one_week_move": -14.4, "four_week_move": -11.3, "twelve_week_move": 91.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.072074, "market_dynamics_buy_signal": false, "relative_strength": 107.928971, "fair_value_gap": -17.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.417, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-14.4% over one week, -11.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "Stock Titan", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "StocksToTrade", "count": 2}, {"label": "marketscreener.com", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 19}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 11}, {"label": "Earnings", "count": 11}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "19", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-14.4% over one week, -11.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 424B5 Q32 Bio Inc For: 15 July By Investing.com"}], "updated_at": "2026-07-16T10:34:54.865821+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}